Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation

Imidazoquinolines (IMDs), such as resiquimod (R848), are of great interest as potential cancer immunotherapies because of their ability to activate Toll-like receptor 7 (TLR7) and/or TLR8 on innate immune cells. Nevertheless, intravenous administration of IMDs causes severe immune-related toxicities...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhagchandani, Sachin H., Vohidov, Farrukh, Milling, Lauren E., Tong, Evelyn Yuzhou, Brown, Christopher M., Ramseier, Michelle L., Liu, Bin, Fessenden, Timothy B., Nguyen, Hung V.-T., Kiel, Gavin R., Won, Lori, Langer, Robert S., Spranger, Stefani, Shalek, Alex K., Irvine, Darrell J., Johnson, Jeremiah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115420/
https://www.ncbi.nlm.nih.gov/pubmed/37075115
http://dx.doi.org/10.1126/sciadv.adg2239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115420/
https://www.ncbi.nlm.nih.gov/pubmed/37075115
http://dx.doi.org/10.1126/sciadv.adg2239

Ejemplares similares